Abstract
Background: Hepatitis C Virus (HCV) is the most common blood-borne infection in the U.S., affecting at least 4 million individuals. In CHC, providers and patients monitor disease status by liver function studies. While providers rely on liver biopsy as the gold standard, patients track alanine aminotransferase levels (ALT). Unfortunately, ALT is not a useful marker of disease progression in CHC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have